| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | November 16, 2023 |
| Accession Number: | 0001140361-23-052681 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | November 16, 2023 |
| Accession Number: | 0001140361-23-052681 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/10/2023 | $7.00 → $10.00 | Market Perform → Outperform | SVB Securities |
| 3/2/2022 | $30.00 → $15.00 | Buy | Benchmark |
| 2/28/2022 | $23.00 → $11.00 | Market Perform | SVB Leerink |
| 2/1/2022 | $24.00 → $11.00 | Outperform → Neutral | Robert W. Baird |
| 2/1/2022 | $24.00 → $11.00 | Outperform → Neutral | Baird |
| 12/2/2021 | $13.00 | Hold | Jefferies |
| 11/8/2021 | $70.00 → $23.00 | Outperform | RBC Capital |
| 11/8/2021 | $40.00 → $23.00 | Market Perform | SVB Leerink |
4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)
4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)
4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)
SVB Securities upgraded Tabula Rasa HealthCare from Market Perform to Outperform and set a new price target of $10.00 from $7.00 previously
Benchmark reiterated coverage of Tabula Rasa HealthCare with a rating of Buy and set a new price target of $15.00 from $30.00 previously
SVB Leerink reiterated coverage of Tabula Rasa HealthCare with a rating of Market Perform and set a new price target of $11.00 from $23.00 previously
Continued Strong Organic Revenue Growth of 24% Second Quarter Adjusted EBITDA of $6.3 Million Increased More Than 3x Compared to Second Quarter 2022 MOORESTOWN, N.J., Aug. 7, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC) ("TRHC" or the "Company"), a leading healthcare company advancing personalized, comprehensive care for value-based care organizations, today reported financial results for the second quarter ended June 30, 2023. Highlights from the second quarter ended June 30, 2023 include: Second quarter revenue from continuing operations of $90.0 million
MOORESTOWN, N.J., July 25, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), will hold a conference call and webcast to discuss its second quarter 2023 financial results Tuesday, August 8, 2023 at 8:30 a.m. EDT. The Company's financial results for the second quarter 2023 ended June 30, 2023, will be released after the close of the market Monday, August 7, 2023. Those interested in participating via webcast in listen-only mode can access the event here. For participants who would like to participate via telephone, please register here to receive the dial-in numbe
First Quarter Results Show Benefits of Consistent Execution on Financial and Strategic Objectives First Quarter Revenue Growth of 32% Compared to First Quarter 2022 Raises Full Year 2023 Revenue and Adjusted EBITDA Guidance MOORESTOWN, N.J., May 8, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC) ("TRHC" or the "Company"), a leading healthcare technology company advancing the safe use of medications, today reported financial results for the first quarter ended March 31, 2023. Highlights from the first quarter ended March 31, 2023, include: First quarter revenu
EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)
EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)
EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)
Rittenhouse Ventures, a leading venture capital firm with over 15 years of experience backing the country's top early-stage software founders, today announced the successful closing of Fund III. The new fund will build on the firm's strong track record of investing in capital-efficient, innovative B2B software, AI and tech-enabled services companies, with a particular focus on the Mid-Atlantic and other underserved regions across the United States. With the close of this fund, Rittenhouse Ventures has over $75M of assets under management. Rittenhouse Ventures Fund III continues the firm's commitment to partnering with emerging leaders in the software industry. "We are thrilled to be able
NEW YORK, Aug. 12, 2023 (GLOBE NEWSWIRE) -- Veritiv Corporation (NYSE:VRTV) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of VRTV to an affiliate of Clayton, Dubilier & Rice, LCC for $170.00 per share in cash for each share of VRTV common stock owned. If you are a VRTV investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Fiesta Restaurant Group, Inc. (NASDAQ:FRGI) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary dutie
Continued Strong Organic Revenue Growth of 24% Second Quarter Adjusted EBITDA of $6.3 Million Increased More Than 3x Compared to Second Quarter 2022 MOORESTOWN, N.J., Aug. 7, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC) ("TRHC" or the "Company"), a leading healthcare company advancing personalized, comprehensive care for value-based care organizations, today reported financial results for the second quarter ended June 30, 2023. Highlights from the second quarter ended June 30, 2023 include: Second quarter revenue from continuing operations of $90.0 million
Appoints Brian Adams as President and Chief Executive Officer and a Member of the Board of Directors, Effective Immediately Appoints Richard W. Rew II as Chief Legal Officer and Corporate Secretary Announces Preliminary Unaudited First Quarter 2023 Revenue Exceeding Guidance MOORESTOWN, N.J., April 13, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC) ("TRHC" or the "Company"), a leading healthcare technology company advancing the safe use of medications, today announced the appointment of Brian Adams as President and Chief Executive Officer. Mr. Adams, who was serving as TRHC's interim Chief Executive Officer since September 2022 and previously served as the Company's Co-Pre
MOORESTOWN, N.J., Nov. 1, 2022 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (TRHC) (NASDAQ:TRHC), a leading healthcare technology company advancing the safe use of medications, today announced the appointment of April D. Gill as Chief Commercial Officer. Ms. Gill has more than 20 years of experience in healthcare with a proven track record exceeding client satisfaction, sales, and profitability goals. In this newly created role, Ms. Gill will oversee development and execution of TRHC's commercialization with broad responsibility for strategy, product, marketing, communication
Drs. Calvin H. Knowlton and Orsula V. Knowlton to retire from the Company Co-President Brian Adams Named Interim CEO Director Michael Purcell Named Independent Board Chairman MOORESTOWN, N.J., Sept. 14, 2022 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (TRHC) (NASDAQ:TRHC), a leading healthcare technology company advancing the safe use of medications, today announced that co-founders Dr. Calvin H. Knowlton, BScPharm, MDiv, PhD, ScD (hon), Chief Executive Officer and Board Chairman, and Dr. Orsula V. Knowlton, PharmD, MBA, Co-President and Chief Marketing and New Business Development Officer, will retire from TRHC and step down as members of the Board of Directors, effective immediately. Dir
SC 13D/A - Tabula Rasa HealthCare, Inc. (0001651561) (Subject)
SC 13G/A - Tabula Rasa HealthCare, Inc. (0001651561) (Subject)
SC 13D/A - Tabula Rasa HealthCare, Inc. (0001651561) (Subject)